PRKDC and cancer: By using CRISPR/Cas9, Wu found that B7-H1 is related to the catalytic subunit of DNA-dependent protein kinases (DNA-PKCs), which promotes or maintains the activation of ERK or P38 MAPK in cancer cells, thus restoring the sensitivity of cancer cells to chemotherapy (62).